Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 By: Benzinga via Benzinga November 01, 2022 at 10:27 AM EDT Upgrades For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in ... Read More >> Related Stocks: AMC Entertainment Holdings Abiomed Inc Acadia Pharmaceutica Akari Therapeutics ADR Anaptysbio Inc Argo Blockchain Plc ADR Atai Life Sciences N.V. Atlas Corp Axsome Thera Banco Santander Brasil S.A. ADR Biomea Fusion Inc Bionomics Limited - American Depository Shares COMPASS Pathways Plc - American Depository Shares Carvana Company Cl A Centerspace Cerevel Therapeutics Hldg Inc Charles Schwab Chemours Company Clearwater Paper Corp Core Scientific, Inc. - Common Stock Edap Tms Sa ADR Emerson Electric Evolent Health Inc Cl A Com Exelixis Inc First Solar Gogo Inc Greenlane Holdings Inc Cl A Guardant Health Inc Horizon Therapeutics Inovio Pharma Instil Bio, Inc. Intellia Thera CS Jasper Therapeutics Inc. Karuna Therapeutics Inc Lantern Pharma Inc Legend Biotech Corp ADR Lennox International Monster Beverage Norfolk Southern Northwestern Energy Group Inc OptimizeRx Corporation - Common Stock Pds Biotechnology Corp Principal Financial Group Ramco-Gershenson Properties Trust Regeneron Pharmaceuticals Reviva Pharmaceuticals Hldg Inc Rocket Pharmaceuticals Inc Sage Therapeutic Com Skechers USA Ord Shs Cl A Steven Maddens Ltd Stryker Corp Tronox Inc Tusimple Holdings Inc Cl A Union Pacific Varonis Systems Inc Ventas Inc Welltower Inc Zymeworks Inc